Drug
Pimecrolimus clinical trials
Also written Elidel and ASM981.
How studies write it
Studies that test it under each name
Studies by the year they started
45 studies that test it; most in 2004 (15)
| Year | Studies |
|---|---|
| 2001 | 1 |
| 2003 | 2 |
| 2004 | 15 |
| 2005 | 7 |
| 2006 | 3 |
| 2007 | 4 |
| 2008 | 1 |
| 2009 | 3 |
| 2010 | 1 |
| 2012 | 1 |
| 2014 | 1 |
| 2015 | 1 |
| 2016 | 2 |
| 2017 | 1 |
| 2019 | 1 |
| 2024 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 26 · Other 19
Novartis (16) · Novartis Pharmaceuticals (3) · LEO Pharma (2) · Children's Hospital of Philadelphia (2) · Technische Universität Dresden (2) · Dermatology Specialists Research (1) · MEDA Pharma GmbH & Co. KG (1) · National Medical Research Center for Children's Health, Russian Federation (1)
Often tested with
Tested in the same studies.
Clobetasol (2) · Betamethasone dipropionate (1) · Betamethasone (1) · Hydrocortisone (1) · Topical Corticosteroid (1)
Related medicines
As reviewed, each with the page that says it.
Studies
Open first, then newest update. How each study uses pimecrolimus is read from its arms, and is right about nine times in ten.
Testing it · 45
- A Phase 3 Study to Evaluate the Efficacy and Safety of Pimecrolimus 0.3% Ophthalmic OintmentTerminatedPhase 3Famy Life Sciences, a Viatris CompanyNCT06400511Written as Pimecrolimus 0.3% Ophthalmic Ointment
- A Multi-Centre Clinical Trial to Evaluate a Left-Right Design in Adults With Mild to Moderate Atopic DermatitisCompletedPhase 1LEO PharmaNCT02103725Written as pimecrolimus 10 mg/g cream
- A Clinical Trial to Compare Topical Agents in Adults With Mild to Moderate Atopic Dermatitis (AD)CompletedPhase 1LEO PharmaNCT02376049Written as Pimecrolimus cream
- A 4 Week Study of Elidel (Pimecrolimus) for the Treatment of Seborrheic DermatitisCompletedPhase 2Dermatology Specialists ResearchNCT00403559Written as Elidel
- 5-Year Safety Study of Pimecrolimus Cream 1% in Infants 3 - 12 Months of Age With Mild to Moderate Atopic DermatitisCompletedPhase 3MEDA Pharma GmbH & Co. KGNCT00120523Written as Pimecrolimus
- Prevention of Development of Transcutaneous Sensitization in Children With Atopic Dermatitis During Their First Year of LifeCompletedPhase 4National Medical Research Center for Children's Health, Russian FederationNCT04900948Written as Pimecrolimus cream 1%
- Safety and Efficacy of Pimecrolimus Ophthalmic Suspension in Patients With Moderate to Severe Keratoconjunctivitis SiccaCompletedPhase 2NovartisNCT00128245Written as Pimecrolimus
- Safety Study of Elidel (Pimecrolimus) 1% Cream to Treat Netherton SyndromeCompletedPhase 1/2Children's Hospital of PhiladelphiaNCT00208026Written as Pimecrolimus 1% Cream
- Study of Generic Pimecrolimus Cream, 1% in the Treatment of Mild to Moderate Atopic DermatitisCompletedPhase 3Glenmark Pharmaceuticals Ltd. IndiaNCT02896101Written as Elidel® (pimecrolimus) Cream
- Efficacy of Topical Pimecrolimus in the Treatment of Pityriasis AlbaStatus unknownPhase 2/3St Joseph University, Beirut, LebanonNCT03834935Written as Elidel (pimecrolimus 1%)
- Cutaneous Lupus Erythematosus and ElidelWithdrawnNot applicableUniversity of LeipzigNCT00222183Written as Elidel (pimecrolimus)
- Open Label Study of Long Term Treatment of Pediatric Treatment of Atopic Dermatitis With Pimecrolimus Cream 1% Within a Usual Clinical SettingCompletedPhase 4Novartis PharmaceuticalsNCT00509990Written as Pimecrolimus
- Safety and Bioequivalence of Pimecrolimus Cream 1% and Elidel R in Treatment of Mild to Moderate Atopic DermatitisCompletedPhase 3Par Pharmaceutical, Inc.NCT03297502Written as pimecrolimus cream 1%
- 1% Topical Pimecrolimus Cream for the Treatment of the Rash Associated With ERBITUXTerminatedPhase 2West Virginia UniversityNCT01692626Written as Pimecrolimus
- Reconstitution With Pimecrolimus Cream 1% of Steroid-damaged Skin in Adults With Atopic DermatitisCompletedPhase 4NovartisNCT00367393Written as Pimecrolimus cream 1%
- Open-label Study to Investigate Systemic Exposure in Adult and Pediatric Atopic Dermatitis Patients Treated 8.5 Days With Pimecrolimus Cream 1% Under OcclusionCompletedPhase 4NovartisNCT00925730Written as Pimecrolimus
- Assessment of Pruritus Improvement With Pimecrolimus Treatment on the Areas Affected by Mild-to-moderate AD, in Patients 2- to 11- Year-oldCompletedPhase 4Novartis PharmaceuticalsNCT00510003Written as Pimecrolimus
- Clinical and Immunohistochemical Effect of Topical Pimecrolimus in Treatment of Oral Lichen PlanusCompletedPhase 4Ain Shams UniversityNCT02443311Written as Pimecrolimus 1% cream
- A Clinical Study in Children and Adolescents With Mild to Moderate Atopic DermatitisCompletedPhase 4BayerNCT00568412Written as Elidel
- Comparison of Skin Thickness Under Treatment With Pimecrolimus 1% Cream, Hydrocortisonacetat 1% Cream, Betamethasonvalerat 0,1% Cream and Clobetasol-17-propionat 0,05% Cream Assessed by Optical Coherence Tomography (OCT) and 20-MHZ UltrasoundCompletedPhase 1Technische Universität DresdenNCT00655512Written as pimecrolimus 1% cream
See all 45 studies that test pimecrolimus →
As the comparator · 10 — what is tested is compared with pimecrolimus
- Treatment of Vulvar Lichen Sclerosus With Corticosteroid Ointment, Calcineurin Inhibitor Ointment, and Platelet-Rich Plasma (PRP) Therapy.Not yet recruitingNot applicableMilosz PietrusNCT07240389Written as Pimecrolimus Cream (Elidel)
- A Study to Evaluate the Safety, Tolerability and Pharmacokinetic Properties of IN-A002 Ointment in Healthy Adult Male Volunteers and Mild to Moderate Atopic Dermatitis PatientsCompletedPhase 1HK inno.N CorporationNCT05729074Written as Elidel Cream 1% (pimecrolimus)
- LEO 29102 Cream in the Treatment of Atopic DermatitisCompletedPhase 2LEO PharmaNCT01037881Written as Elidel®
- A Study of Crisaborole Ointment 2%; Crisaborole Vehicle; TCS and TCI in Subjects Aged ≥ 2 Years, With Mild-moderate ADTerminatedPhase 4PfizerNCT03539601Written as Pimecrolimus cream, 1%
- Study of Equivalence of Generic Pimecrolimus Cream 1% and Elidel® 1% in Subjects With Mild to Moderate Atopic DermatitisCompletedPhase 3Actavis Inc.NCT02791308Written as Pimecrolimus Cream 1% (Valeant)
- A Study to Evaluate the Safety and Efficacy of PAC-14028 Cream in Atopic DermatitisCompletedPhase 2Amorepacific CorporationNCT02583022Written as Elidel cream 1%
- Comparison Study Between Protopic (Tacrolimus Ointment) and Elidel (Pimecrolimus Cream) in Pediatric Patients With Mild Atopic DermatitisCompletedPhase 4Astellas Pharma IncNCT00667160Written as pimecrolimus cream
- Comparison Study Between Protopic (Tacrolimus Ointment) and Elidel (Pimecrolimus Cream) in Treating Pediatric Patients With Atopic DermatitisCompletedPhase 4Astellas Pharma IncNCT00666159Written as pimecrolimus cream
- A Comparison Study Between Protopic (Tacrolimus) Ointment and Elidel (Pimecrolimus) Cream in Treating Subjects With Atopic DermatitisCompletedPhase 4Astellas Pharma IncNCT00666302Written as pimecrolimus cream
- Epiceram Versus Elidel for Treatment of Mild to Moderate Atopic DermatitisCompletedPhase 4Ceragenix PharmaceuticalsNCT00460083Written as Elidel(R) (pimecrolimus 1%)
Codes
What other systems call pimecrolimus · ClinicalTrials.gg INT004129
- MeSH (NLM) C117268pimecrolimusConfirmed ClinicalTrials.gov, NLM, Wikidata
- UNII (FDA) 7KYV510875PIMECROLIMUSConfirmed FDA, NLM, Wikidata
- RxNorm 321952Confirmed FDA, Wikidata
- Wikidata Q417489pimecrolimusConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C47671PimecrolimusOne source FDA
- DrugBank DB00337One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C117268 | pimecrolimus | Confirmed ClinicalTrials.gov, NLM, Wikidata |
| UNII (FDA) | 7KYV510875 | PIMECROLIMUS | Confirmed FDA, NLM, Wikidata |
| RxNorm | 321952 | — | Confirmed FDA, Wikidata |
| Wikidata | Q417489 | pimecrolimus | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C47671 | Pimecrolimus | One source FDA |
| DrugBank | DB00337 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.